Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Replacement Therapy in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
NCT06733350Phase 4Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Testosterone TEPI patch in Hypogonadism (3 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Gleason grade progression at 5 years, Discontinuation of active surveillance at 5 years and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
Testosterone TEPI patch
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT06733350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733350.